Price T Rowe Associates Inc. MD Increases Stock Holdings in Janux Therapeutics, Inc. $JANX

Key Points

• Price T Rowe Associates Inc. MD increased its holdings in Janux Therapeutics by 25.5%, now owning approximately 1.39 million shares worth about $37.61 million.
• Other institutional investors significantly boosted their stakes in Janux Therapeutics, with Bank of America and Wellington Management making substantial increases of 1,165.6% and 3,592.9%, respectively during the 4th quarter.
• Janux Therapeutics has a high consensus rating of "Buy" among analysts, with an average target price set at $86.90.

Price T Rowe Associates Inc. MD lifted its stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 25.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,392,826 shares of the company's stock after purchasing an additional 282,848 shares during the quarter. Price T Rowe Associates Inc. MD owned about 2.35% of Janux Therapeutics worth $37,607,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the stock. Erste Asset Management GmbH purchased a new stake in shares of Janux Therapeutics during the first quarter worth approximately $786,000. Aberdeen Group plc raised its stake in shares of Janux Therapeutics by 250.8% during the first quarter. Aberdeen Group plc now owns 224,788 shares of the company's stock worth $6,069,000 after purchasing an additional 160,716 shares during the last quarter. E Fund Management Co. Ltd. raised its stake in shares of Janux Therapeutics by 6.3% during the first quarter. E Fund Management Co. Ltd. now owns 68,644 shares of the company's stock worth $1,853,000 after purchasing an additional 4,076 shares during the last quarter. Russell Investments Group Ltd. raised its stake in shares of Janux Therapeutics by 15,117.4% during the first quarter. Russell Investments Group Ltd. now owns 153,848 shares of the company's stock worth $4,154,000 after purchasing an additional 152,837 shares during the last quarter. Finally, Nuveen LLC purchased a new stake in shares of Janux Therapeutics during the first quarter worth approximately $3,339,000. Hedge funds and other institutional investors own 75.39% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on JANX shares. Piper Sandler started coverage on Janux Therapeutics in a research note on Monday, August 18th. They set an "overweight" rating and a $42.00 price target for the company. Raymond James Financial assumed coverage on Janux Therapeutics in a research report on Friday, July 11th. They issued an "outperform" rating and a $65.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat, Janux Therapeutics has an average rating of "Buy" and an average price target of $86.90.

Janux Therapeutics Stock Performance

NASDAQ:JANX traded up $0.14 during trading hours on Tuesday, hitting $22.86. The company's stock had a trading volume of 904,571 shares, compared to its average volume of 787,388. The business's 50-day moving average is $24.50 and its two-hundred day moving average is $26.96. The company has a market capitalization of $1.37 billion, a PE ratio of -12.70 and a beta of 2.84. Janux Therapeutics, Inc. has a 52-week low of $21.97 and a 52-week high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.07). As a group, analysts predict that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.